[Comparison of patient therapy adherence of two structural different memory clinics].
There are more than 100 memory clinics established in Germany, Austria and German-speaking Switzerland. We compared the impact of the structure of two German memory clinics (Erlangen and Nuremberg) on therapeutic outcome. 483 patients suffering from dementia with indication for antidementive therapy were included in this study. The data ascertainment included patient-related data, the mini mental score, comorbidity as well as psychiatric drug therapy. After a mean follow-up of 3.7 years, we performed a single cross-sectional survey covering over 90 % of patients to assess clinical course and adherence to therapy. The patients of the Erlangen University Memory Clinic were significantly younger (69.8 +/- 9.49 vs. 74.6 +/- 10.7 years; p = 0.01) and had a better mini mental score at their first presentation (20.9 +/- 9.4 vs. 19.5 +/- 5.9; p = 0.02). They showed a non-significantly faster disease progression (as measured by mini mental decline per year), than the patients from Nuremberg. Concerning the allocation of diagnosis, more late onset-dementias and dementias of a mixed type were treated at the Nuremberg clinic. At the university clinic, more dementias were of unclassified origin. Concomitant drug therapies, death rates and therapy adherence (53 %) were not different between the two clinics. The two memory clinics under investigation differed in patient age, disease severity and diagnostic assessment. Still, parameters of therapeutic outcome showed converging results.
Weih
M
M
Psychiatrische und Psychotherapeutische Klinik, Universitätsklinikum Erlangen, Erlangen. markus.weih@uk-erlangen.de
Sulimma
A-K
AK
Lehfeld
H
H
Niklewski
G
G
Sonnenberg
M
M
Richter-Schmidinger
T
T
Alexopoulos
P
P
Grässel
E
E
Kornhuber
J
J
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D003430:Cross-Sectional Studies; D003704:Dementia / Q000150:complications; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008569:Memory Disorders / Q000453:epidemiology / Q000523:psychology* / Q000628:therapy*; D009483:Neuropsychological Tests; D018697:Nootropic Agents / Q000627:therapeutic use; D010349:Patient Compliance / Q000706:statistics & numerical data*; D011569:Psychiatric Status Rating Scales; D011597:Psychomotor Performance; D016896:Treatment Outcome
D018697:Nootropic Agents